Novo Nordisk Trial Flop Ripples Through Denmark’s Stock Market
Disappointing data from Novo Nordisk A/S is sending shockwaves across equities in Denmark, dragging the wider market down and underscoring how tightly the country’s fortunes are tied to the obesity-drug maker.
📰 Original Source
Read full article at Bloomberg →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.